Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
A phase 2 trial of Palbociclib, Temozolomide, FOLFIRI in ewing sarcoma and rhabdomyosarcoma, run by Pfizer, active and no longer recruiting.
Overview
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors is a phase 2 interventional study registered as NCT03709680 by Pfizer, with 128 participants enrolled, started 2019-05-24 and due to reach its primary completion in 2024-08-26. Interventions recorded: Palbociclib, Temozolomide, Irinotecan, Topotecan, Cyclophosphamide. Conditions listed: Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- CollectionSt. Baldrick's Foundation
Shares Rhabdomyosarcoma, Ewing sarcoma, Medulloblastoma.
- TrialLurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
- TrialCAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Shares Ewing sarcoma, Temozolomide.
- TrialVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
Shares Palbociclib, Pfizer (incl. Seagen).
- InstitutionNationwide Children's Hospital
Shares Rhabdomyosarcoma, Ewing sarcoma, Medulloblastoma.
- CollectionAlex's Lemonade Stand Foundation (ALSF)
Shares Rhabdomyosarcoma, Ewing sarcoma, Medulloblastoma.
- TrialStudy for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
Shares Palbociclib, Pfizer (incl. Seagen).
- TrialPF-07104091 as a Single Agent and in Combination Therapy
Shares Palbociclib, Pfizer (incl. Seagen).